

Chagas Disease Drug-North America Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/C1171614EE9MEN.html>

Date: March 2018

Pages: 155

Price: US\$ 3,480.00 (Single User License)

ID: C1171614EE9MEN

Abstracts

Report Summary

Chagas Disease Drug-North America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Chagas Disease Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole North America and Regional Market Size of Chagas Disease Drug 2013-2017, and development forecast 2018-2023

Main market players of Chagas Disease Drug in North America, with company and product introduction, position in the Chagas Disease Drug market

Market status and development trend of Chagas Disease Drug by types and applications

Cost and profit status of Chagas Disease Drug, and marketing status

Market growth drivers and challenges

The report segments the North America Chagas Disease Drug market as:

North America Chagas Disease Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

United States

Canada

Mexico

North America Chagas Disease Drug Market: Product Type Segment Analysis

(Consumption Volume, Average Price, Revenue, Market Share and Trend

2013-2023):

Cz-007

Cz-008

D-121

DNDI-0690

EPLBS-1246

EPLBS-967

Others

North America Chagas Disease Drug Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Hospital

Clinic

Others

North America Chagas Disease Drug Market: Players Segment Analysis (Company and
Product introduction, Chagas Disease Drug Sales Volume, Revenue, Price and Gross
Margin):

AstraZeneca Plc

Bayer AG

Daiichi Sankyo Co Ltd

Eisai Co Ltd

GlaxoSmithKline Plc

Grupo Praxis Pharmaceutical SA

Humanigen Inc

Kancera AB

Merck & Co Inc

Novartis AG

Oblita Therapeutics BVBA

Sanofi

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF CHAGAS DISEASE DRUG

- 1.1 Definition of Chagas Disease Drug in This Report
- 1.2 Commercial Types of Chagas Disease Drug
 - 1.2.1 Cz-007
 - 1.2.2 Cz-008
 - 1.2.3 D-121
 - 1.2.4 DNDI-0690
 - 1.2.5 EPLBS-1246
 - 1.2.6 EPLBS-967
 - 1.2.7 Others
- 1.3 Downstream Application of Chagas Disease Drug
 - 1.3.1 Hospital
 - 1.3.2 Clinic
 - 1.3.3 Others
- 1.4 Development History of Chagas Disease Drug
- 1.5 Market Status and Trend of Chagas Disease Drug 2013-2023
 - 1.5.1 North America Chagas Disease Drug Market Status and Trend 2013-2023
 - 1.5.2 Regional Chagas Disease Drug Market Status and Trend 2013-2023

CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Chagas Disease Drug in North America 2013-2017
- 2.2 Consumption Market of Chagas Disease Drug in North America by Regions
 - 2.2.1 Consumption Volume of Chagas Disease Drug in North America by Regions
 - 2.2.2 Revenue of Chagas Disease Drug in North America by Regions
- 2.3 Market Analysis of Chagas Disease Drug in North America by Regions
 - 2.3.1 Market Analysis of Chagas Disease Drug in United States 2013-2017
 - 2.3.2 Market Analysis of Chagas Disease Drug in Canada 2013-2017
 - 2.3.3 Market Analysis of Chagas Disease Drug in Mexico 2013-2017
- 2.4 Market Development Forecast of Chagas Disease Drug in North America 2018-2023
 - 2.4.1 Market Development Forecast of Chagas Disease Drug in North America 2018-2023
 - 2.4.2 Market Development Forecast of Chagas Disease Drug by Regions 2018-2023

CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole North America Market Status by Types

3.1.1 Consumption Volume of Chagas Disease Drug in North America by Types

3.1.2 Revenue of Chagas Disease Drug in North America by Types

3.2 North America Market Status by Types in Major Countries

3.2.1 Market Status by Types in United States

3.2.2 Market Status by Types in Canada

3.2.3 Market Status by Types in Mexico

3.3 Market Forecast of Chagas Disease Drug in North America by Types

CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Chagas Disease Drug in North America by Downstream Industry

4.2 Demand Volume of Chagas Disease Drug by Downstream Industry in Major Countries

4.2.1 Demand Volume of Chagas Disease Drug by Downstream Industry in United States

4.2.2 Demand Volume of Chagas Disease Drug by Downstream Industry in Canada

4.2.3 Demand Volume of Chagas Disease Drug by Downstream Industry in Mexico

4.3 Market Forecast of Chagas Disease Drug in North America by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CHAGAS DISEASE DRUG

5.1 North America Economy Situation and Trend Overview

5.2 Chagas Disease Drug Downstream Industry Situation and Trend Overview

CHAPTER 6 CHAGAS DISEASE DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA

6.1 Sales Volume of Chagas Disease Drug in North America by Major Players

6.2 Revenue of Chagas Disease Drug in North America by Major Players

6.3 Basic Information of Chagas Disease Drug by Major Players

6.3.1 Headquarters Location and Established Time of Chagas Disease Drug Major Players

6.3.2 Employees and Revenue Level of Chagas Disease Drug Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

CHAPTER 7 CHAGAS DISEASE DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 AstraZeneca Plc

- 7.1.1 Company profile
- 7.1.2 Representative Chagas Disease Drug Product
- 7.1.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of AstraZeneca Plc

7.2 Bayer AG

- 7.2.1 Company profile
- 7.2.2 Representative Chagas Disease Drug Product
- 7.2.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of Bayer AG

7.3 Daiichi Sankyo Co Ltd

- 7.3.1 Company profile
- 7.3.2 Representative Chagas Disease Drug Product
- 7.3.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of Daiichi Sankyo Co Ltd

7.4 Eisai Co Ltd

- 7.4.1 Company profile
- 7.4.2 Representative Chagas Disease Drug Product
- 7.4.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of Eisai Co Ltd

7.5 GlaxoSmithKline Plc

- 7.5.1 Company profile
- 7.5.2 Representative Chagas Disease Drug Product
- 7.5.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc

7.6 Grupo Praxis Pharmaceutical SA

- 7.6.1 Company profile
- 7.6.2 Representative Chagas Disease Drug Product
- 7.6.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of Grupo Praxis Pharmaceutical SA

7.7 Humanigen Inc

- 7.7.1 Company profile
- 7.7.2 Representative Chagas Disease Drug Product
- 7.7.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of Humanigen Inc

Inc

7.8 Kancera AB

7.8.1 Company profile

7.8.2 Representative Chagas Disease Drug Product

7.8.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of Kancera AB

7.9 Merck & Co Inc

7.9.1 Company profile

7.9.2 Representative Chagas Disease Drug Product

7.9.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of Merck & Co

Inc

7.10 Novartis AG

7.10.1 Company profile

7.10.2 Representative Chagas Disease Drug Product

7.10.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of Novartis AG

7.11 Oblita Therapeutics BVBA

7.11.1 Company profile

7.11.2 Representative Chagas Disease Drug Product

7.11.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of Oblita

Therapeutics BVBA

7.12 Sanofi

7.12.1 Company profile

7.12.2 Representative Chagas Disease Drug Product

7.12.3 Chagas Disease Drug Sales, Revenue, Price and Gross Margin of Sanofi

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CHAGAS DISEASE DRUG

8.1 Industry Chain of Chagas Disease Drug

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CHAGAS DISEASE DRUG

9.1 Cost Structure Analysis of Chagas Disease Drug

9.2 Raw Materials Cost Analysis of Chagas Disease Drug

9.3 Labor Cost Analysis of Chagas Disease Drug

9.4 Manufacturing Expenses Analysis of Chagas Disease Drug

CHAPTER 10 MARKETING STATUS ANALYSIS OF CHAGAS DISEASE DRUG

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Chagas Disease Drug-North America Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/C1171614EE9MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C1171614EE9MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970